Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 7/20 | 0.56 |
| ▸ | CA1 | P00915 | 7/20 | 0.56 |
| ▸ | CA2 | P00918 | 7/20 | 0.56 |
| ▸ | CA9 | Q16790 | 7/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | STK17B | O94768 | 1/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12284963 | 0.92 | CA12 (0.49) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL1901959 | 0.90 | IDO1 (0.51) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL21441648 | 0.88 | CA12 (0.46) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL21878211 | 0.87 | CA12 (0.59) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL19263787 | 0.86 | CA12 (0.47) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL6937740 | 0.83 | CA12 (0.62) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL1063374 | 0.81 | CA12 (0.60) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL6937743 | 0.81 | CA12 (0.60) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL4112468 | 0.81 | CA12 (0.60) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL35211336 | 0.80 | CA12 (0.59) | CA12CA1CA2CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9200104-B2 | Polymer | WARWICK EFFECT POLYMERS LIMITED (GB) | 2015-12-01 | — | — | US | disclosed |
| US-9200104-B2 | Polymer | WARWICK EFFECT POLYMERS LIMITED (GB) | 2015-12-01 | — | — | US | disclosed |
| US-20130295040-A1 | POLYMER | WARWICK EFFECT POLYMERS LTD (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130295040-A1 | POLYMER | WARWICK EFFECT POLYMERS LTD (US) | 2013-11-07 | — | — | US | disclosed |
| US-8436104-B2 | Polymer | WARWICK EFFECT POLYMERS LIMITED (GB) | 2013-05-07 | — | — | US | disclosed |
| US-8436104-B2 | Polymer | WARWICK EFFECT POLYMERS LIMITED (GB) | 2013-05-07 | — | — | US | disclosed |
| US-8436104-B2 | Polymer | WARWICK EFFECT POLYMERS LIMITED (GB) | 2013-05-07 | — | — | US | disclosed |
| US-8197847-B2 | Process for making polymers and supports comprising pendant sugar side groups | WARWICK EFFECT POLYMERS LTD. (GB) | 2012-06-12 | — | — | US | disclosed |
| US-20090082224-A1 | POLYMERS | WARWICK EFFECT POLYMERS LIMITED (GB) | 2009-03-26 | — | — | US | disclosed |
| US-20080300348-A1 | Polymer | WARWICK EFFECT POLYMERS LIMITED | 2008-12-04 | — | — | US | disclosed |
| US-20080300348-A1 | Polymer | WARWICK EFFECT POLYMERS LIMITED | 2008-12-04 | — | — | US | disclosed |
| EP-1784430-A1 | LIVING RADICAL POLYMERIZATION INITIATOR COMPRISING A FUNCTIONAL GROUP CAPABLE OF REACTING WITH POLYEPTIDES OR THE LIKE, COMB POLYMER OBTAINED THEREWITH , POLYPEPTIDE CONJUGATES AND DRUGS OBTAINED THEREFROM. | Warwick Effect Polymers Limited (GB) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006003352-A1 | LIVING RADICAL POLYMERIZATION INITIATOR COMPRISING A FUNCTIONAL GROUP CAPABLE OF REACTING WITH POLYEPTIDES OR THE LIKE, COMB POLYMER OBTAINED THEREWITH, POLYPEPTIDE CONJUGATES AND DRUGS OBTAINED THEREFROM | WARWICK EFFECT POLYMERS LIMITED (GB) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130295040-A1 | POLYMER | PCNA, PARG, COASY | CA12 1397/4885CA1 2153/4885CA2 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.